Application of human interferon containing pharmaceutical composition in preparation of medicine for preventing and treating virus infection of respiratory tract

A technology of interferon and composition, which is applied in the field of medicine to achieve the effect of small side effects and favorable use

Inactive Publication Date: 2007-03-14
北京金迪克生物技术有限责任公司 +1
View PDF0 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, α, β, and γ have been studied more and used in clinical treatment; the clinical application value of other types of interferon is still under study

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human interferon containing pharmaceutical composition in preparation of medicine for preventing and treating virus infection of respiratory tract
  • Application of human interferon containing pharmaceutical composition in preparation of medicine for preventing and treating virus infection of respiratory tract
  • Application of human interferon containing pharmaceutical composition in preparation of medicine for preventing and treating virus infection of respiratory tract

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0077] According to the method of pharmacy, prepare the spray, the volume of each bottle is 3.65 ml, in which the active content of recombinant human interferon-α2b (Beijing Yuance Pharmaceutical Co., Ltd.) is 3 million IU / ml, and the content of human albumin is 0.5 %, the benzyl alcohol content was 0.5%, the glycan content was 0.1%, and the phosphate buffer concentration was 20 mmol / L.

[0078] Each bottle of the product in this example is 3 million IU / mL*3.65mL, and a preventive course of treatment is 1 bottle, which is used for 3-5 days, which not only ensures the effective dose of interferon for topical use, but also limits the dosage.

[0079] The animal has been tested, and its irritation to mucous membranes and skin lesions is similar to that of normal saline, and no serious side effects are found. Compared with the IntronA powder injection in the United States, its side effects are moderate, and the side effects of the product in this example can be ignored. , it can b...

Embodiment 2

[0082] According to the preparation method of the injection, the recombinant human interferon-α1a (Beijing Yuance Pharmaceutical Co., Ltd.) was added to a phosphate buffer solution with a pH of 7, so that the active content of the interferon was 1 million IU / mL, and benzyl alcohol was added as a preservative. , the weight content is 0.5%.

Embodiment 3

[0084] Referring to the method of Example 2, the obtained injection was divided into vials of 1.5 ml each, and freeze-dried to obtain freeze-dried powder injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a medicine compound with interferon. Wherein, said compound can be used to prepare the medicine that prevents and resists virus infection of respiratory tract. Said compound contains interferon and other auxiliary materials. Wherein, said interferon can be alpha2b, alpha1b, beta, Omega, k, lambada, epsilon and other I type; said auxiliary materials contains protector and baffle solution; and said interferon can be recombined interferon or/and the ones made by other methods; the auxiliary materials can be acidic buffer, protein, manna sugar, polyose, and benzoic alcohol to realize baffle, stabilize and corrosion-resistant functions.

Description

Technical field: [0001] The invention relates to the application of a pharmaceutical composition containing human interferon in the preparation of a medicine for preventing or / and treating respiratory virus infection, and belongs to the field of medicine. Background technique: [0002] Interferons (IFNs) are a class of proteins that have broad-spectrum antiviral, anti-cell division, immunomodulatory activities and affect cell metabolism, growth and differentiation in different ways at least on the same cells. Newly synthesized RNA and protein. It is a kind of important cytokine. After nearly 30 years of clinical research and application, it shows that it is an important broad-spectrum antiviral and antitumor therapeutic drug. [0003] Type main feature Clinical application and possible clinical use Interferon -α Is a type I interferon; about 23 varieties. There are about 13 subtypes that are studied in detail. Molecular The amount ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/21A61P31/12A61P31/16A61P31/22
Inventor 候云德
Owner 北京金迪克生物技术有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap